MCF-7

Last updated
MCF-7 cells MCF-7 Cells.jpg
MCF-7 cells

MCF-7 is a breast cancer cell line. [1] MCF-7 is the acronym of Michigan Cancer Foundation-7, referring to the institute in Detroit where the cell line was established in 1973 by Herbert Soule and co-workers. [2] The Michigan Cancer Foundation is now known as the Barbara Ann Karmanos Cancer Institute. [3]

Contents

MCF-7 and two other breast cancer cell lines, named T-47D and MDA-MB-231, account for more than two-thirds of all abstracts reporting studies on mentioned breast cancer cell lines, as concluded from a Medline-based survey. [4]

Isolation

MCF-7 was isolated in 1970 from a 69-year-old woman. [1] The patient, Frances Mallon died in 1970 due to metastatic breast cancer. [5] Her cells were the source of much of current knowledge about breast cancer. [2] [6]

Prior to MCF-7, it was not possible for cancer researchers to obtain a mammary cell line that was capable of living longer than a few months. [7]

Uses

MCF-7 has potential for new drug development, including anti-cancer drug testing, anti-estrogen drug resistance and antiplatelet drug development. [8]

Antiproliferation

Tumor necrosis factor alpha (TNF alpha) inhibits the growth of MCF-7 breast cancer cells. Treatment with anti-estrogens can modulate the secretion of insulin-like growth factor binding proteins. Omega-3 and 6 fatty acids such as EPA, DHA and AA has been reported to inhibit MCF-7 cell line growth and proliferation. [9]

Many studies indicate that the insulin-like growth factor 1 receptor is a crucial therapeutic target for treating cancer in MCF-7 cell lines. [10] One notably effective treatment strategy is silencing this receptor using siRNA packaged in nanoparticles, which significantly suppresses the growth and proliferation of MCF-7 cancer cells. [11]

The results of IC50 determination (Liu et al.) of compounds of Melilotus officinalis (Linn.) Pall. were published during 2018. [12]

Tamoxifen increases FasL and TNF-α. [13]

Characteristics of MCF-7 cells

MCF-7 cells have the following characteristics: [2] [6] [4] [14] [15] [16]

This cell line retained several characteristics of differentiated mammary epithelium, including the ability to process estradiol via cytoplasmic estrogen receptors and the capability of forming domes.[ citation needed ]

References

  1. 1 2 Al-hussaniy, Hany; AL-Zobaidy, Mohammed (2024-06-01). "Cytotoxic Effect of YH239-EE and Its Enantiomer on MCF7 Cell Line". Asian Pacific Journal of Cancer Prevention . 25 (6): 2133–2138. doi:10.31557/APJCP.2024.25.6.2133. ISSN   2476-762X. PMC   11382848 . PMID   38918676.
  2. 1 2 3 Soule, HD; Vazquez J; Long A; Albert S; Brennan M. (1973). "A human cell line from a pleural effusion derived from a breast carcinoma". Journal of the National Cancer Institute . 51 (5): 1409–1416. doi:10.1093/jnci/51.5.1409. PMID   4357757.
  3. ↑ http://www.cancer.gov "NCI Cancer Bulletin for April 29, 2008 - National Cancer Institute". Archived from the original on 2010-05-27. Retrieved 2010-04-28. Retrieved on 2010-04-28
  4. 1 2 Lacroix, M; Leclercq G. (2004). "Relevance of breast cancer cell lines as models for breast tumours: an update". Breast Research and Treatment . 83 (3): 249–289. doi:10.1023/B:BREA.0000014042.54925.cc. PMID   14758095. S2CID   207628369.
  5. ↑ Lee, A. V.; Oesterreich, S.; Davidson, N. E. (2015-03-31). "MCF-7 Cells--Changing the Course of Breast Cancer Research and Care for 45 Years". JNCI Journal of the National Cancer Institute. 107 (7) djv073. doi:10.1093/jnci/djv073. ISSN   0027-8874. PMID   25828948.
  6. 1 2 Levenson, AS; Jordan VC. (1997). "MCF-7: the first hormone-responsive breast cancer cell line". Cancer Research . 57 (15): 3071–3078. PMID   9242427.
  7. ↑ Glodek, Cass, Ph.D., "A History of the Michigan Cancer Foundation, the Beginnings & Growth of Detroit's Anticancer Movement," 1990, page 68, Michigan Cancer Foundation, Detroit.
  8. 1 2 3 Comşa, Şerban; Cîmpean, Anca Maria; Raica, Marius (2015-06-01). "The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research". Anticancer Research . 35 (6): 3147–3154. ISSN   0250-7005. PMID   26026074. History - description of ER in the MCF-7 cells in 1973
  9. ↑ Mansara, Prakash P.; Deshpande, Rashmi A.; Vaidya, Milind M.; Kaul-Ghanekar, Ruchika (1 September 2015). "Differential Ratios of Omega Fatty Acids (AA/EPA+DHA) Modulate Growth, Lipid Peroxidation and Expression of Tumor Regulatory MARBPs in Breast Cancer Cell Lines MCF7 and MDA-MB-231". PLOS ONE. 10 (9) e0136542. Bibcode:2015PLoSO..1036542M. doi: 10.1371/journal.pone.0136542 . ISSN   1932-6203. PMC   4556657 . PMID   26325577.
  10. ↑ Mennati, Afsaneh; Rostamizadeh, Kobra; Manjili, Hamidreza Kheiri; Fathi, Mojtaba; Danafar, Hossein (2022-03-01). "Co-delivery of siRNA and lycopene encapsulated hybrid lipid nanoparticles for dual silencing of insulin-like growth factor 1 receptor in MCF-7 breast cancer cell line" . International Journal of Biological Macromolecules. 200: 335–349. doi:10.1016/j.ijbiomac.2021.12.197. ISSN   0141-8130.
  11. ↑ Mennati, Afsaneh; Rostamizadeh, Kobra; Fathi, Mojtaba (March 2025). "Dual silencing of integrin αvβ3 receptor and insulin-like growth factor 1 receptor using mPEG-PCL/DDAB hybrid nanoparticle loaded siRNA in breast cancer therapy: An in vitro study on MCF-7 cells". International Journal of Biological Macromolecules. 294 139334. doi:10.1016/j.ijbiomac.2024.139334. ISSN   1879-0003. PMID   39743068.
  12. ↑ Yu-Ting Liu; et al. (29 January 2018). "Chemical Constituents and Antioxidant, Anti-Inflammatory and Anti-Tumor Activities of Melilotus officinalis (Linn.) Pall". Molecules . 23 (2). China: MDPI: 271. doi: 10.3390/molecules23020271 . PMC   6017420 . PMID   29382154.
  13. ↑ Tamilselvan Subramani; et al. (25 November 2013). "Vitamin C suppresses cell death in MCF-7 human breast cancer cells induced by tamoxifen: Abstract". J Cell Mol Med . 18 (2): 305–313. doi:10.1111/jcmm.12188. PMC   3930417 . PMID   24266867.
  14. ↑ Ross, DT; Perou CM. (2001). "A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines". Disease Markers. 17 (2): 99–109. doi: 10.1155/2001/850531 . PMC   3850857 . PMID   11673656.
  15. ↑ Charafe-Jauffret, E; Ginestier C; Monville F; Finetti P; Adelaide J; Cervera N; Fekairi S; Xerri L; Jacquemier J; Birnbaum D; Bertucci F. (2006). "Gene expression profiling of breast cell lines identifies potential new basal markers". Oncogene . 25 (15): 2273–2284. doi:10.1038/sj.onc.1209254. PMID   16288205.
  16. ↑ Lacroix, M; Toillon RA; Leclercq G. (2006). "p53 and breast cancer, an update". Endocrine-Related Cancer . 13 (2). Bioscientifica: 293–325. doi: 10.1677/erc.1.01172 . PMID   16728565.
  17. ↑ Samuel C. Brooks; Elizabeth R. Locke; Herbert D. Soule (10 September 1973). "Estrogen Receptor in a Human Cell Line (MCF-7) from Breast Carcinoma". Journal of Biological Chemistry . 248 (17). ASBMB: Elsevier B.V.: 6251–6253. doi: 10.1016/S0021-9258(19)43537-0 . PMID   4353636 – via COMŞA et al. Anticancer Research June 2015, 35 (6).
  18. ↑ Sflomos, George; Dormoy, Valerian; Metsalu, Tauno; Jeitziner, Rachel; Battista, Laura; Scabia, Valentina; Raffoul, Wassim; Delaloye, Jean-Francois; Treboux, Assya (2016). "A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response". Cancer Cell. 29 (3): 407–422. doi: 10.1016/j.ccell.2016.02.002 . PMID   26947176.
  19. ↑ Cosmic. "COSMIC: Sample overview for 1289391". cancer.sanger.ac.uk. Retrieved 2017-05-10.
  20. ↑ Vasudevan, Krishna M.; Barbie, David A.; Davies, Michael A.; Rabinovsky, Rosalia; McNear, Chontelle J.; Kim, Jessica J.; Hennessy, Bryan T.; Tseng, Hsiuyi; Pochanard, Panisa (2009-07-07). "AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer". Cancer Cell. 16 (1): 21–32. doi:10.1016/j.ccr.2009.04.012. ISSN   1878-3686. PMC   2752826 . PMID   19573809.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.